TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07671911: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Sponsor: Trevi Therapeutics · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 306 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,772,230

Rescue Site Savings

+$2,498,490

Unlock Full NCT07671911 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07671911 Rescue Dossier →